Viatris (VTRS) EPS (Diluted) Growth (1y) (2020 - 2026)
Viatris (VTRS) EPS (Diluted) Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -304.28% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 1.28% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -15.70% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 13.47% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -2,504.14% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 30.20% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 385.28% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -99.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,504.14% |
| Mar 31, 2026 | 105.88% |
| Dec 31, 2025 | 32.88% |
| Sep 30, 2025 | -239.39% |
| Jun 30, 2025 | 98.57% |
| Mar 31, 2025 | -2,809.06% |
| Dec 31, 2024 | 31.77% |
| Sep 30, 2024 | -71.24% |
| Jun 30, 2024 | -224.92% |
| Mar 31, 2024 | -49.47% |
| Dec 31, 2023 | -176.37% |
| Sep 30, 2023 | -5.59% |
| Jun 30, 2023 | -14.95% |
| Mar 31, 2023 | -43.36% |
| Dec 31, 2022 | 480.61% |
| Sep 30, 2022 | 13.23% |
| Jun 30, 2022 | 211.66% |
| Mar 31, 2022 | 138.30% |
| Dec 31, 2021 | 85.67% |
| Sep 30, 2021 | 178.62% |